Respiratory Research, 2011 Background Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations.
Szema Anthony M +5 more
doaj +1 more source
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis [PDF]
, 2009 M. E. Hettema +5 more
openalex +1 more source
, 2005 This article discusses recent guidelines and management of common respiratory conditions and reviews key papers published over the past five years.peer ...
Caruana Montalto, Brendan +1 more
core
Influence of hydroxybosentan on determination of bosentan in human plasma [PDF]
, 2015 Edyta Gilant +4 more
openalex +1 more source
Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy [PDF]
, 2008 Nancy Porhownik +2 more
openalex +1 more source
Brazilian Journal of Medical and Biological Research, 2007 Chagas' disease, caused by the protozoan Trypanosoma cruzi, is a major cause of cardiovascular disability in countries where it is endemic. Damage to the heart microvasculature has been proposed to be an important factor in the pathogenesis of heart ...
E. Roffê +9 more
doaj
EFFECT OF BOSENTAN ON THE EXERCISE TOLERANCE AND PFT SCORE IN PULMONARY HYPERTENSION ASSOCIATED TO ADVANCED COPD [PDF]
, 2007 Giuseppe Valerio +6 more
openalex +1 more source
Experience with bosentan in pulmonary arterial hypertension secondary to systemic sclerosis [PDF]
, 2006 Caroline Barranco
openalex +1 more source
Pulse Wave Velocity in Systemic Sclerosis: Potential Beneficial Effects of Bosentan on Forearm Arterial Stiffness? An Exploratory Study [PDF]
, 2020 A.M. van Roon +2 more
openalex +1 more source
Human medicines European public assessment report (EPAR): Stayveer, bosentan monohydrate, Hypertension, Pulmonary,Scleroderma, Systemic, Date of authorisation: 24/06/2013, Revision: 9, Status: Authorised [PDF]
, 2019 Kernel Networks Inc.
openalex +1 more source